Hemostatic Paste Having Surface Enriched with Hemostasis-Promoting Agents and Devices for Delivery

Abstract

The present invention is directed to a hemostatic semi-solid paste material comprising a bioabsorbable carrier hemostatic material; and a supplemental hemostatic agent; wherein the paste material has an elongated form extending along a lengthwise axis with an aspect ratio of at least 3; wherein the paste is self-supporting and syringe extrudable; and wherein the supplemental hemostatic agent has a non-homogenous distribution profile across a cross-section taken across the lengthwise axis. In another aspect, the present invention relates to devices for forming and expressing the hemostatic material.

Claims

1. A hemostatic semi-solid paste material comprising: a) a bioabsorbable carrier hemostatic material; and b) a supplemental hemostatic agent; wherein the paste material has an elongated form extending along a lengthwise axis with an aspect ratio of at least 3, the paste material is self-supporting and syringe extrudable, and the supplemental hemostatic agent has a non-homogenous distribution profile across a cross-section taken across the lengthwise axis.

2. The hemostatic material of claim 1, wherein said elongated form is enriched with said supplemental hemostatic agent that is present exclusively or primarily on an outside surface of the elongated form or in an outside layer of the elongated form.

3. The hemostatic material of claim 2, wherein an internal portion of said elongated form is contains substantially none of said supplemental hemostatic agent.

4. The hemostatic paste material of claim 1, wherein said carrier hemostatic material is gelatin or collagen.

5. The hemostatic paste material of claim 4, wherein said paste comprises thermally cross-linked gelatin and water.

6. The hemostatic paste material of claim 1, wherein said supplemental hemostatic agent is an oxidized cellulosic material, a hemostatically active enzyme, a platelet aggregating peptide, a hemostatic solvent extract of a natural material, or combinations thereof.

7. The hemostatic paste material of claim 6, wherein said supplemental hemostatic agent comprises oxidized regenerated cellulose in a form of a powder.

8. The hemostatic paste material of claim 6, wherein said supplemental hemostatic agent comprises thrombin.

9. The hemostatic paste material of claim 8, wherein said supplemental hemostatic agent comprises thrombin mixed with gelatin.

10. A delivery device for forming and expressing the hemostatic paste material of claim 1 comprising: a) a first syringe containing the carrier material; b) a second syringe containing at least the supplemental hemostatic agent; wherein said first and second syringes are joined an integrated unit and connected to a coaxial expression tip configured for simultaneous expression of the carrier material and the supplemental hemostatic agent; wherein the coaxial expression tip comprises an external tube and an internal tube positioned within said external tube, with a gap between the external tube and an internal tube.

11. The delivery device of claim 10, wherein the external tube and the internal tube are open at a distal end, the first syringe is connected to said internal tube at a proximal end and expresses the carrier material through said internal tube and the second syringe is connected to said external tube at the proximal end and expresses the supplemental hemostatic agent though said gap, and the device co-expresses said hemostatic carrier and said supplemental hemostatic agent in the elongated form with substantially no mixing or incomplete mixing of the hemostatic carrier material and supplemental hemostatic agent.

12. The delivery device of claim 11, wherein an opening of the internal tube is offset from the distal end.

13. The delivery device of claim 10, wherein said second syringe contains a mixture comprising the supplemental hemostatic agent and the carrier material.

14. The delivery device of claim 10, wherein the external tube is closed at a distal end and the internal tube is open at the distal end, the internal tube is in fluid communication with the gap through at least one opening in a wall of the internal tube, the first syringe is connected to said internal tube at a proximal end and expresses the carrier material through said internal tube and the second syringe is connected to said external tube at the proximal end and expresses the supplemental hemostatic agent though said gap.

15. A delivery device for forming and expressing the hemostatic paste material of claim 1 comprising: a) a first syringe containing the carrier material; b) a second syringe containing at least the supplemental hemostatic agent; wherein said first and second syringes are an integrated unit that provides simultaneous expression of the carrier material and the supplemental hemostatic agent, the first syringe expresses the carrier material through a first expression cannula and the second syringe expresses the supplemental hemostatic agent in a form of a spray through a second expression cannula, the first and second expression cannulas terminate with closely positioned openings and the supplemental hemostatic agent is sprayed onto said carrier material through said first expression cannula.

16. A delivery device for forming and expressing the hemostatic paste material of claim 1 comprising: a) a first syringe containing the carrier material; and b) a coaxial applicator tip; wherein said coaxial applicator tip has an external tube and an internal tube positioned within said external tube, with a gap between the external tube and an internal tube; the first syringe is connected to said internal tube at a proximal end and expresses the carrier material through said internal tube, the supplemental hemostatic agent is contained within said gap, the internal tube is open at a distal end and the external tube is closed at the distal end and at the proximal end, and the internal tube is in fluid communication with the gap through at least one opening in a wall of the internal tube.

17. The device of claim 16, wherein said external tube is formed of an elastic material and the supplemental hemostatic agent is compressed by the external tube.

18. A method of treating a wound comprising the step of applying the hemostatic paste material of claim 1 onto and/or into the wound of a patient.

19. A method of making the hemostatic paste material of claim 1, comprising the steps: a) connecting a first syringe containing the carrier material and a second syringe containing at least the supplemental hemostatic agent to a coaxial expression tip; b) co-expressing through the coaxial tip the carrier material and the supplemental hemostatic agent in a combined elongated form substantially with no mixing or incomplete mixing.

Description

BRIEF DESCRIPTION OF FIGURES

[0028] FIGS. 1a, 1b, 1c show schematic perspective and cross-sectional views of embodiments of the present invention.

[0029] FIGS. 2a, 2b, 2c show comparative results of in vitro testing.

[0030] FIGS. 3a, 3b show photo images corresponding to prior art.

[0031] FIGS. 4a, 4b show photo images of embodiments of the present invention.

[0032] FIGS. 5a, 5b, 5c show comparative results of in vitro testing.

[0033] FIGS. 6a, 6b show photo images of embodiments of the present invention.

[0034] FIGS. 7a, 7b show photo images of embodiments of the present invention.

[0035] FIGS. 8a, 8b, 8c show comparative results of in vitro testing.

[0036] FIG. 9 shows a schematic cross-sectional view of an embodiment of the present invention.

[0037] FIG. 10 shows a schematic cross-sectional view of an embodiment of the present invention.

[0038] FIG. 11 shows a schematic cross-sectional view of an embodiment of the present invention.

[0039] FIG. 12 shows a schematic cross-sectional view of an embodiment of the present invention.

[0040] FIG. 13 shows a schematic cross-sectional view of an embodiment of the present invention.

[0041] FIG. 14 shows a schematic cross-sectional view of an embodiment of the present invention.

DETAILED DESCRIPTION

[0042] Hemostatic paste (such as gelatin particles mixed with and or dispersed in water or aqueous solutions) is frequently homogeneously mixed with an additional or supplemental hemostatic agent (such as thrombin) that activates, initiates, accelerates or otherwise enhances the efficacy of the hemostatic cascade once in contact with blood plasma prior to administration onto a wound. The additional hemostatic agent, which is consequently largely contained within the bulk of the paste, is not exposed to the bleeding wound surface at the earliest possible time. The additional hemostatic agent which is in the bulk of the paste thus may not be able to immediately contribute to hemostatic biologic processes on bleeding surfaces, potentially adding to unnecessary costs and need to absorb the agent which was not timely available for hemostasis.

[0043] According to an embodiment of the present invention, an absorbable carrier hemostatic composition, preferably a flowable viscous semi-liquid fluid or paste, has an elongated rod-like or “noodle-like” shape with a surface enriched with a hemostasis promoting agent. In one embodiment, the flowable viscous semi-liquid fluid or paste having elongated rod-like shape comprises a scaffold or matrix or carrier, onto which a hemostatic agent or a layer of absorbable material enriched with a hemostasis promoting agent is deposited.

[0044] The additional or supplemental hemostatic agent can be thrombin or thrombin equivalent or any other hemostasis-promoting, and/or clotting promoting, and/or platelet aggregation promoting active material, such as enzyme, protein, peptide, molecule, natural material, modified natural material such as oxidized cellulose (OC) or oxidized regenerated cellulose (ORC), solvent extract, or particle, or particle aggregates.

[0045] U.S. Pat. No. 9,539,358 by Yi-Lan Wang, Guanghui Zhang “Oxidized regenerated cellulose hemostatic powders and methods of making”, which is incorporated by reference herein in its entirety, discloses various ORC coarse and fine fiber particles as well as particle aggregates that can be utilized as supplemental hemostatic agent in practicing the present invention.

[0046] U.S. Pat. Nos. 9,717,820; 9,149,511 by Yi-Lan Wang, Guanghui Zhang “Procoagulant peptides and their derivatives and uses therefor”, incorporated by reference herein, discloses hemostatically active peptides that can be utilized as supplemental hemostatic agent in practicing the present invention.

[0047] U.S. Pat. No. 9,028,851 by Yi-Lan Wang et al. “Hemostatic materials and devices with galvanic particulates” incorporated by reference herein, discloses hemostatically active galvanic particulates that can be utilized as supplemental hemostatic agent in practicing the present invention.

[0048] U.S. Patent Application Publication No. 20120164224 by Yi-Lan Wang et al. “Hemostatic Preparation Containing an Extract of Golden Moss” incorporated by reference herein, discloses hemostatically active Extract of Golden Moss plant that can be utilized as supplemental hemostatic agent in practicing the present invention.

[0049] Referring now to FIG. 1, an embodiment of the present invention shown. FIG. 1a shows a schematic perspective view of elongated hemostatic paste shape 50 having an inside portion 52 comprising absorbable carrier hemostatic material not enriched with additional hemostasis promoting agents, or enriched to a lesser extent with additional hemostasis promoting agents, said inside portion 52 surrounded by an outside or surface portion or layer 54 which is enriched with hemostasis promoting agents than inside portion 52. As shown, elongated shape 50 running along a lengthwise axis 51 and can be straight or bent and undulating in a wavy form along axis 51. FIG. 1b shows a schematic cross-sectional view of hemostatic paste shape 50 with inside portion 52 and enriched surface layer 54 shown. According to an embodiment of the present invention, the concentration of hemostasis promoting agents is higher in the surface portion 54 relative to inside portion 52.

[0050] Elongated hemostatic paste shape 50 can have any cross-sectional shape depending on the expression tip, such as elliptical, square, rectangular, triangular, etc., most typically circular cross-section. The diameter can be any convenient diameter, such as ranging from 0.25 mm to 15 mm, more preferably 0.5 mm to 5 mm, such as 1, 2, 3 ,5, 7 mm diameter. The length of hemostatic paste shape 50 having elongated rod-like or “noodle-like” shape can be any convenient length, such as from 2 mm to 300 mm, such as 5, 10, 20, 30, 50, 100 mm. Surface layer 54 encompasses a range from the agent being only adhering to the surface to enriching surface layer 54 (zero depth penetration) to a depth of from 0 to 25, 50, 100, 200, 300, 500, 1000, 2000 microns, such as 50, 100 or 300 microns. Alternatively, surface layer 54 comprises from 0.1% to 25% of overall thickness or diameter of hemostatic paste shape 50, such as 1, 5, 10% of overall thickness or diameter.

[0051] As shown in FIG. 1b, lengthwise dimension L of elongated hemostatic paste shape 50 is much larger than largest transverse or cross-sectional dimension T, defining aspect ratio A as a ratio of L to T, or A=L/T. Aspect ratio is preferably at least 3, more preferably at least 5, such as 5, 10, 15, 20, 50, 100 or higher. For elongated hemostatic paste shape 50 having diameter of 2 mm and length of 30 mm, A=15.

[0052] As shown in FIG. 1c, showing cross-sectional view of elongated hemostatic paste shape 50 with cross-section taken across the lengthwise axis 51, the supplemental hemostatic agent has a non-homogenous distribution profile across a cross-section taken across the lengthwise axis 51, with higher concentration within outside or surface portion or layer 54 close to the surface of elongated form 50, and lower concentration or no supplemental hemostatic agent in the inside portion 52.

[0053] Advantageously, it is postulated that for the inventive test article, comprising a given quantity Q of hemostasis-promoting agent disposed on or in surface layer 54, the hemostatic performance is better than performance of a comparative test article, comprising the same given quantity Q of hemostasis-promoting agent homogeneously mixed into elongated hemostatic paste shape 50.

[0054] Further, it is postulated that for the inventive test article, comprising a given quantity Q of hemostasis-promoting agent disposed on or in surface layer 54, the hemostatic performance is equal to or better than performance of a comparative test article, comprising larger quantity of hemostasis-promoting agent homogeneously mixed into elongated hemostatic paste shape 50, such as quantity equal to 1.5 Q, 2 Q, 3 Q, 5 Q, 10 Q, or similar.

[0055] Advantageously, according to the present invention, the hemostatic performance is either improved when the same quantity of hemostatic agent is disposed on or in surface layer 54, comparative to the hemostasis-promoting agent homogeneously mixed into elongated hemostatic paste shape 50. Alternatively, or additionally, the same hemostatic performance can be achieved with a smaller quantity of hemostatic agent disposed on or in surface layer 54, comparative to the hemostasis-promoting agent homogeneously mixed into elongated hemostatic paste shape 50.

[0056] According to the present invention, presence of hemostasis promoting agents disposed on or in surface layer 54 provides for faster access of the agents to the bleeding site and/or tissue in the first several seconds or minutes when hemostasis is established; on the contrary the hemostasis promoting agents that are buried deeply inside elongated hemostatic paste shape 50 have lesser availability to affect hemostasis during the critical first several seconds or minutes when hemostasis is sought.

EXAMPLE 1

Gelatin Paste with ORC Coating Testing for Clotting with Porcine Blood

[0057] A gelatin paste commercially available as SURGIFLO® Hemostatic Matrix, available from Ethicon, Inc., Somerville, N.J., (which comprises sterile, absorbable cross-linked gelatin paste intended for hemostatic use by applying to a bleeding surface) was prepared according to the Instructions for use by mixing with normal saline. The gelatin paste was then formed into elongated rod-like shape by expression from a syringe and coated on its surface with 10% by weight of oxidized regenerated cellulose (ORC) fine fibers. As a comparative test, the gelatin paste was also homogeneously mixed with 10% by weight of ORC fine fibers and then then formed into elongated rod-like shapes by expression from a syringe.

[0058] ORC coarse and fine fiber can be obtained as follows. A reference is made to the U.S. Pat. No. 9,539,358 Oxidized regenerated cellulose hemostatic powders and methods of making, which is incorporated by reference herein in its entirety for all purposes.

[0059] One method of obtaining ORC coarse and fine fiber directly from cellulosic materials, such as ORC fabric or non-woven products such as these discussed above is as follows.

[0060] Briefly, manufacturing process starts with ORC material, such as SURGICEL® Original absorbable hemostat, as which is cut into 1- to 2-inch wide sections before the material is fed into a blade that cuts the fabric into smaller pieces. The cut ORC fabric pieces are then ground into intermediate ORC fine fibers by two consecutive milling processes (hammer milling and air classifier milling). In an alternative embodiment, the cut ORC fabric pieces are converted directly into intermediate fine fibers in a ball mill.

[0061] More specifically, one process for manufacturing the ORC fine fiber comprises the steps of: a) slitting and cutting of cellulosic source material; b) milling the resulting material from step a); c) a second milling step in an air classifier.

[0062] Slitting and cutting can preferably be performed to slit and cut fabric into appropriate size pieces that are between approximately 1 inch by 3 inches or 2 inches by 3 inches, though smaller pieces can also be used. The main operations performed for slitting and cutting are to unwind a roll of fabric, slit the fabric into strips, cut the strips to size and deliver the cut pieces into the first milling step. Many cutting and slitting machines are known and commercially available, such as AZCO Model FTW-1000 available from AZCO. In the first milling step, processed pieces of cellulosic fabric are converted from an intermediate coarse fiber produced in the slitting and cutting step to a material having a D90 value of less than 452 μm and D50 value of less than 218 μm, while having minimal impact on the color index and water-soluble content of the material. Many machines for milling are commercially available, such as Models DASO6 and WJ-RS-D6A manufactured by Fitzpatrick, which are hammer mill type milling machines, equipped with a 497 micron round screen and a set of blades that breaks down the fabric until it passes through the screen to produce intermediate coarse cellulosic fiber.

[0063] In an exemplary processing run, mill speed can be about 7000 RPM; processing temperature at less than 80° C.; screen size between 1534 and 9004; number of blades as 8 (2 impellers each); blade type as a 225 knife, impact type blades; blade orientation set as “impact”.

[0064] At this stage in the preferred process, the size of the intermediate coarse fiber produced in the first milling step is further reduced to a D90 value of less than 177 μm and a D50 value of less than 95 μm while keeping a minimal impact on the color index and water-soluble content of the material. Many machines are available for second milling step, such as an Air Classifier/F10 Quadro Fine Grind from Quadro.

[0065] Intermediate coarse fiber from the first milling step can be fed at a controlled rate into the second mill and passed through two milling chambers that are separated by a milling screen. The material can be pulled through the milling chamber by an air blower. The intermediate coarse fiber can be processed through the air classifier equipment three times to obtain the desired size. At the end of the second milling step, the intermediate fine fiber can be collected.

[0066] In an exemplary processing run, a Quadro Air Classifier F10 can be used in the second milling step with a milling speed of 8400 rpm, blower speed of 1800 rpm, 0.0018″ round hole screen and 3 passes. ORC intermediate fine fiber can be also produced in one step by ball milling instead of the two steps milling steps as described above. In an alternative ball milling embodiment, 50 g of pre-cut ORC fabric (2″×2″) is ball milled with 12 high-density Zirconia (zirconium dioxide ZrO2, 20 mm in diameter; Glen Mills Inc., Clifton, N.J., USA) by placing the balls and the samples in a 500-mL grinding jar. The jar is clamped into the latching brackets and then counterbalanced on the planetary ball mill PM100; Retsch, Inc., Newtown, Pa., USA). The milling is then performed bi-directionally at 450 rpm for 20 minutes.

[0067] A quantity of 10% w/w of ORC fine powder was used to enrich surface to make surface enriched (inventive embodiment) and homogeneously mixed (comparative test) paste was then added to a vial containing 4 ml of porcine blood. FIG. 2 shows a photograph of three vials containing porcine blood after 4 minutes. FIG. 2a shows control (porcine blood, no additions). FIG. 2b shows comparative test whereby to the vial with porcine blood was added the gelatin paste homogeneously mixed with 10% by weight of ORC fine fibers. FIG. 2c shows the inventive embodiment whereby to the vial with porcine blood was added the gelatin paste enriched only on its surface with 10% by weight of ORC fine fibers. As can be seen from FIG. 2, pure blood shows no clotting, gelatin paste homogeneously mixed with ORC shows minor clotting of blood, while the inventive embodiment of gelatin paste enriched only on its surface with the same amount of ORC fine fibers shows substantial/complete clotting.

[0068] Not shown in FIG. 2 is another control test whereby gelatin paste not enriched by ORC at all was also added to the vial with porcine blood. No clotting was observed.

[0069] Thus, the inventive paste enriched on its surface with hemostatic agents demonstrates an advantage over homogeneously admixed agent in the same quantity and over paste having no added agent.

EXAMPLE 2

Preparation of Gelatin Paste and Gelatin Paste with Homogenously Admixed Agents for Testing of In Vitro Clotting with Human Blood

[0070] Surgiflo™ gelatin was thoroughly mixed with 2 ml saline (0.9% NaCl Irrigation USP). FIGS. 3a, 3b show photos at different magnifications of the resulted expressed elongated hemostatic paste shapes, not coated with any agents and not mixed with any agents.

[0071] The scale is shown in FIGS. 3a, 4a, 7a by a 200-micron bar marker. FIGS. 3b, 4b, 7b are magnified 1.6 times vs. photos in FIGS. 3a, 4a, 7a.

[0072] To prepare comparative testing samples, Surgiflo™ gelatin was thoroughly mixed with 2 ml saline (0.9% NaCl Irrigation USP) and further homogenously mixed with hemostatic agents, including ORC fine powders, ORC coarse fibers, thrombin, and then expressed as elongated hemostatic paste shapes having homogenously admixed one of the above agents uniformly distributed through the paste.

EXAMPLE 3

Preparation of Gelatin Paste Surface Coated with ORC Fine Fibers and Testing of In Vitro Clotting with Human Blood

[0073] Elongated hemostatic paste shapes prepared as described in Example 2 were coated on the surface by ORC fine fibers powder characterized by d50: 78 μm and d90: 157 μm.

[0074] FIGS. 4a, 4b show photos at different magnifications of the resulted expressed elongated hemostatic paste shapes.

[0075] Elongated hemostatic paste shapes were then added (about 1 g, see Table 1) to vials containing sodium citrate treated (3.2%) human blood (4 ml) with no mixing.

[0076] FIGS. 5a and 5b show photographs of vials in different views immediately after adding to the vials comparative test article (elongated hemostatic paste shapes comprising gelatin homogenously mixed with fine ORC fibers as described in Example 2), indicated with letter “M”; and the inventive test article (elongated hemostatic paste shapes comprising gelatin surface coated with fine ORC fibers), indicated with letter “C”.

[0077] After 3 minutes, the vials were turned over with the bottoms of the vials facing upwardly, to characterize clotting. FIG. 5c shows photographs of vials after turning the vials over. The inventive test article indicated with letter “C” shows all blood substantially clotted and remaining in the upward portion of the turned over vial, indicating strong clotting performance. The comparative test article indicated with letter “M” shows all blood substantially migrated down and not remaining in the upward portion of the turned over vial, indicating very poor clotting performance. Thus, the inventive test article of elongated hemostatic paste shapes comprising gelatin surface coated with fine ORC fibers performed much better than test articles with homogenously admixed agent.

[0078] Table 1 shows the amounts of gelatin and added ORC coating used, whereby on average about 32% of ORC coating by weight was added in 4 testing replicates.

TABLE-US-00001 TABLE 1 Amounts of gelatin and added ORC coating used Sample Weight of Weight of gelatin coated Amount of No. gelatin, g with ORC, g ORC added, g A-1 0.75 0.990 0.240 A-2 0.78 0.928 0.148 A-3 0.81 1.108 0.298 A-4 0.8 1.121 0.321 AVERAGE 0.785 1.037 0.252 Coating % 32.07%

[0079] Table 2 shows experimental measurements to quantify clotting.

TABLE-US-00002 TABLE 2 Experimental measurements to quantify clotting, 3 replicates TEST 1 TEST 2 TEST 3 Gelatin Gelatin Gelatin Gelatin Gelatin Gelatin mixed coated mixed coated with mixed coated with ORC with ORC with ORC ORC with ORC with ORC vial + cap weight, g 14.509 14.625 14.034 14.521 14.921 14.263 Paste weight, g 1.148 1.088 1.003 1.006 1.242 1.212 Blood weight, g 3.938 4.034 4.024 3.983 3.832 3.992 Paste + blood 5.086 5.122 5.027 4.989 5.074 5.204 weight, g total vial, cap, paste, 19.595 19.747 19.061 19.51 19.995 19.467 blood weight, g weight after turning 15.883 19.509 15.002 19.157 15.532 18.834 over and draining any flowable fraction, g flowable/moveable 3.712 0.238 4.059 0.353 4.463 0.633 fraction, g remaining non- 27.02 95.35 19.26 92.92 12.04 87.84 flowable clotted fraction, %

[0080] As shown in Table 2, measurements performed during the testing indicated that in the comparative test articles (gelatin homogenously mixed with ORC), remaining non-flowable clotted fraction was low, such as only 27, 19, 12% of the original content of the vial. For the inventive test article (gelatin on the surface coated with ORC), remaining non-flowable clotted fraction was very high, such as 95, 93, 88% of the original content of the vial, indicating much better clotting performance of the inventive surface coated test articles.

EXAMPLE 4

Preparation of Gelatin Paste Coated with Coarse ORC Fibers

[0081] Elongated hemostatic paste shapes prepared as described in Example 2 were coated on the surface by coarse ORC fibers powder characterized by d50: 157 μm, d90: 296 μm. ORC coarse fibers were dyed with 1.4% (w/v) of Methylene blue in 95% ethanol (Sigma-Aldrich) to improve visibility of the coating.

[0082] FIGS. 6a, 6b show two photos at different magnifications of the resulted expressed elongated hemostatic paste shapes.

EXAMPLE 5

Preparation of Gelatin Paste Coated with Thrombin and Testing of In Vitro Clotting with Human Blood

[0083] Elongated hemostatic paste shapes prepared as described in Example 2 were coated on the surface with finely ground thrombin powder. Thrombin was obtained from the Surgiflo® kit and then milled to form a powder. FIGS. 7a, 7b show two photos at different magnifications of the resulted expressed elongated hemostatic paste shapes coated with milled thrombin powder.

[0084] FIGS. 8a and 8b show photographs of vials in different views immediately after adding to the vials a comparative test article (elongated hemostatic paste shapes comprising gelatin homogenously mixed with thrombin), indicated with letter “M”; and the inventive test article (elongated hemostatic paste shapes comprising gelatin surface coated with milled thrombin powder), indicated with letter “C”.

[0085] After 3 minutes, the vials were turned over with the bottoms of the vials facing upwardly, to characterize clotting. FIG. 8c shows photographs of vials after turning the vials over. The inventive test article indicated with letter “C” shows all blood substantially clotted and remaining in the upward portion of the turned over vial, indicating strong clotting performance. The comparative test article indicated with letter “M” shows blood, while somewhat clotted, substantially migrated down and not remaining in the upward portion of the turned over vial, indicating much weaker clotting performance vs. the coated test article of the present invention. Thus, the inventive test article of elongated hemostatic paste shapes comprising gelatin surface coated with thrombin performed substantially better than test articles with homogenously admixed thrombin as hemostatic agent.

[0086] Table 3 shows the amounts of gelatin and added thrombin powder coating used, whereby on average about 36% of thrombin coating by weight was added.

TABLE-US-00003 TABLE 3 Amounts of gelatin and added thrombin coating used, 4 replicates Sample Weight of Weight of gelatin coated Amount of No. gelatin, g with ORC, g ORC added, g B-1 0.104 0.136 0.032 B-2 0.121 0.173 0.052 B-3 0.101 0.145 0.044 B-4 0.127 0.165 0.038 AVE 0.113 0.155 0.042 Coating % 36.64%

[0087] Table 4 shows experimental measurements to quantify clotting in thrombin testing. Note that if clot formed but has moved from the vial upon turning vial over, it was considered a weak clot and a part of drained flowable/moveable fraction.

TABLE-US-00004 TABLE 4 Experimental measurements to quantify clotting, 3 replicates TEST 1 TEST 2 TEST 3 Gelatin mixed Gelatin coated Gelatin Gelatin Gelatin Gelatin with with mixed with coated with mixed with coated with Thrombin Thrombin Thrombin Thrombin Thrombin Thrombin vial + cap weight, 14.616 14.556 14.503 14.764 14.892 14.931 g Paste weight, g 0.553 0.552 0.503 0.502 0.631 0.611 Blood weight, g 4.083 3.997 4.001 3.83 3.972 3.892 Paste + blood 4.636 4.549 4.504 4.332 4.603 4.503 weight, g total vial, cap, 19.252 19.105 19.007 19.096 19.495 19.434 paste, blood weight, g weight after 15.082 19.009 15.104 18.789 15.323 19.198 turning over and draining any flowable/ moveable fraction, g flowable/moveable 4.17 0.096 3.903 0.307 4.172 0.236 fraction, g remaining non- 10.05 97.89 13.34 92.91 9.36 94.75 flowable clotted fraction, %

[0088] As shown in Table 4, measurements performed during the testing indicated that in the comparative test articles (gelatin paste homogenously mixed with thrombin), remaining non-flowable clotted fraction was low, such as only 10, 13, 9% of the original content of the vial. For the inventive test article (gelatin paste coated with thrombin), remaining non-flowable clotted fraction was very high, such as 98, 93, 95% of the original content of the vial, indicating much better clotting performance of the inventive coated test articles.

Delivery Devices

Paste Coated by Enriched Paste

[0089] According to embodiments of the present invention, there are provided delivery devices for making and expressing elongated hemostatic paste shapes 50 having outside or surface portion or layer 54 which is enriched with hemostasis promoting agents than inside portion 52.

[0090] Referring now to FIG. 9, an embodiment of the present invention shown in a schematic cross-sectional view. Delivery device 10 comprises a dual barrel syringe comprising a first barrel hollow body 20 and a second barrel hollow body 30, with pistons 24 and 34 slidably disposed inside first body 20 and second body 30. Pistons 24 and 34 are simultaneously actuated by plungers 26 and 36 terminating in a unified handle 23 at a proximal end 11. First body 20 and second body 30 at a distal end 12 have expression cannulas 22 and 32 through which a first flowable material 28 contained inside first body 20 and a second flowable material 38 contained inside second body 30 can be simultaneously co-expressed onto a wound through a coaxial expression nozzle or expression tip 40, which is open at a distal end 12. Coaxial expression tip 40 comprises internal tube 44 for expression of first material 28, with tube 44 located inside and within an external tube 42 serving for expression of second material 38. As shown, tube 42 surrounds tube 44 with a gap 46 between tubes allowing second material 38 to move alongside and outside of tube 44. Both materials 28 and 38 exit coaxial expression tip 40 jointly as elongated rod-like or noodle-like shape, with second material 38 attaching onto outside of first material 28, forming elongated hemostatic paste shape 50 having an inside portion 52 comprising first material 28 and surrounded by an outside or surface portion or layer 54 comprising second material 38.

[0091] The size or volume or diameters of first barrel hollow body 20 and second barrel hollow body 30 can be the same, or different as shown in FIG. 9, whereby second barrel hollow body 30 can be smaller diameter as shown, same diameter (not shown), or larger diameter (not shown).

[0092] In one embodiment, first material 28 comprises bioabsorbable carrier hemostatic material that comprises gelatin, collagen, or similar viscous flowable paste suitable for expression onto/into wounds. Second material 38 comprises a supplemental hemostatic agent or hemostasis promoting agent, such as thrombin powder, thrombin solution, ORC, OC, or similar, or mixtures thereof, optionally homogenously mixed with a thickener or filler or carrier hemostatic material, such as gelatin or collagen or similar viscous flowable paste, forming second material 38 that is enriched with additional hemostasis promoting agent. Preferably, both materials 28 and 38 have similar viscosity, such as viscosity within 0%-30% difference, such as 5, 10, 20% viscosity difference or less.

[0093] In operation, in one embodiment, gelatin paste is filled as first material 28 into first body 20 and gelatin paste (as a thickener or filler) premixed with thrombin is filled into second body 30 as second material 38. Depressing handle 23 towards distal end 12 is advancing plungers 26 and 36 and pistons 24 and 34 towards distal end 12 inside bodies 20, 30, thus forming at the exit of coaxial expression tip 40 elongated hemostatic paste shape 50 having an inside portion 52 comprising gelatin as first material 28 and surrounded by surface layer 54 comprising gelatin/thrombin mixture as second material 38.

[0094] Preferably, flow of first material 28 second material 38 is a laminar flow whereby materials advance side by side substantially without mixing.

[0095] Coaxial expression tip 40 can have tube 44 and tube 42 open and terminating at distal end 12 at the same point or at the same distance from proximal end 11, as shown in FIG. 9. In an alternative embodiment, coaxial expression tip 40 can have tube 44 and tube 42 open and terminating at distal end 12 at offset positions or at different distances from proximal end 11. As shown in FIG. 10, in one embodiment, tube 44 can terminate closer to proximate end 11, compared to tube 42, with the difference being from about 0.2 mm to about 10 mm, such as 1, 2, 5, 7 mm. As shown, opening of internal tube 44 is offset from distal end 12 compared to opening of external tube 42.

[0096] Referring now to FIG. 11, an embodiment of the present invention is shown in a schematic cross-sectional view, like the embodiment of FIG. 9, but having a manifold 47 onto which coaxial expression tip 40 is mounted, with manifold 47 connected to expression cannulas 22 and 32 via connecting adaptors 48, which can be press-fit connectors, screw-on connectors, luer connectors, or similar.

[0097] The size or volume or diameters of first barrel hollow body 20 and second barrel hollow body 30 can be the same, or different. As shown in FIG. 11, second barrel hollow body 30 can be of the same diameter as first barrel hollow body 20.

Paste Coated by Solution or Suspension

[0098] Referring now to FIG. 12, an embodiment of the present invention shown in a schematic cross-sectional view, like the embodiments of FIGS. 9, 11, but having coaxial expression tip 40 whereby tube 42 for expression of second material 38 is not open at distal end 12, but closed. Tube 44 has at least one coating aperture 45, preferably a plurality of coating apertures 45, opening a fluid communication between tube 44 and tube 42, with aperture 45 formed in the wall of tube 44.

[0099] In operation, as materials 28 and 38 advance within tip 40, material 38 moves through gap 46 and aperture 45 and enters tube 44, then continuing alongside material 28 through tube 44 towards exiting expression tip 40 and forming at least partially coated elongated hemostatic paste shape 50 having an inside portion 52 comprising first material 28 and at least partially surrounded or partially coated by layer 54 comprising second material 38. Second material 38 can be in a form of traces on surface of first material 28.

[0100] Second material 38 comprises gelatin or collagen or similar lower viscosity flowable solution enriched by homogenously mixing with a hemostasis promoting agent, such as thrombin powder, thrombin solution, ORC, OC, or similar. More preferably, second material comprises aqueous solution of thrombin, or suspension of ORC powder.

Paste Coated by Spray of Liquid or Powder

[0101] Referring now to FIG. 13, an embodiment of the present invention shown in a schematic cross-sectional view, with no coaxial expression tip 40. In this embodiment, expression cannulas 22 and 32 terminate with closely positioned openings at distal end 12. Cannula 22 configured to express first flowable material 28, while cannula 32 configured to spray second flowable material 38 onto first material 28 as it is being expressed, forming elongated hemostatic paste shape 50 having an inside portion 52 comprising first material 28 and at least partially surrounded by surface portion 54 comprising second material 38. Second material 38 can be in a form of particles or spots on surface of first material 28.

[0102] Second material 38 comprises lower viscosity flowable solution such as thrombin solution. Alternatively, second material 38 comprises fine powder, such as thrombin powder or ORC powder, expressed from cannula 32 with the help of air flow, such as forced air or air bellows (not shown).

Paste Coated by ORC or Thrombin Powder Contained in an Enclosed Applicator

[0103] Referring now to FIG. 14, an embodiment of the present invention shown in a schematic cross-sectional view. Delivery device 10a comprises a syringe comprising a first barrel hollow body 20 with piston 24 slidably disposed inside first body 20. Piston 24 is actuated by plunger 26 terminating in a unified handle 23 at a proximal end 11. First body 20 at a distal end 12 has expression cannula 22 through which first flowable material 28 contained inside first body 20 can be expressed onto a wound.

[0104] An applicator 49 of this embodiment is like coaxial expression tip 40 shown in FIG. 12. Tube 42 for expression of second material 38 is closed at both proximal end 11 and distal end 12. Tube 44 has at least one coating aperture 45, preferably a plurality of coating apertures 45, opening a fluid communication between tube 44 and tube 42, with aperture 45 formed in the wall of tube 44.

[0105] Applicator 49 contains fine hemostatic agent powder, such as thrombin powder, ORC powder, or similar as second material 38, and is attached to expression cannula 22 via connecting adaptor 48, which can be press-fit connector, screw-on connector, luer connector, or similar Applicator 49 comprises tube 44 for expression of first material 28, tube 44 is located inside and within tube 42. As shown, tube 42 surrounds tube 44 with a gap 46 between tubes. Second material 38 is contained within gap 46. Tube 42 is closed.

[0106] In operation, as material 28 advances through cannula 22 upon actuation of piston 24, material 28 enters applicator 49 tube 44 and entrains some of second material 38 exposed through apertures 45. Material 28 then is exiting applicator 49 through tube 44 and forming at least partially coated elongated hemostatic paste shape 50 having an inside portion 52 comprising first material 28 and at least partially surrounded or partially coated by layer 54 comprising second material 38. Second material 38 can be in a form of traces on surface of first material 28. Second material 38 can be in a form of particles or spots on surface of first material 28.

[0107] In one embodiment, tube 42 is formed of an elastic material, and is expanded or distended upon filling with second material 38 in the form of powder, thus providing compression force onto second material 38 configured to facilitate expression of material 38 through apertures 45 upon contact with first material 28 moving though tube 44.

[0108] Second material can be a powdered substance with average particle sizes ranging from about 20 to 1500 microns, more preferably 50 to 800 microns, such as 50, 100, 200, 300, 400 microns. Apertures 45 are configured to allow powdered material 38 to go through in a controlled way. In some embodiments apertures 45 have dimensions 10% to 500% larger than average particle size, such as 25, 40, 50, 75, 100%, 200%, 300% larger apertures. In some embodiments, apertures 45 are round apertures with diameter of from 100 to 500 microns.

Hemostatic Paste Extrudability and Self-Supporting Properties

[0109] According to the present invention embodiments, semi-solid and flowable paste is extrudable from devices of the present invention as an elongated form with aspect ratio of at least 3, flowable from the nozzles of the extrusion devices and maintaining elongated high aspect ratio form upon extrusion.

[0110] Upon extrusion, semi-solid paste comprises a self-supporting, shape-keeping construct, which is characterized by accepting and keeping the shape of the nozzle through which it was extruded while also being pliable and adaptable to be packed in a wound or spread over a wound. Paste is self-supporting and after expression, the paste maintains its elongated shape and form on a surface onto which the paste was expressed for at least 30s, and not immediately changing shape without any applied force, as a regular liquid would do. On the other hand, the paste being semi-solid, the paste can be kneaded, deformed, spread over tissue, and/or packed into a wound by applying force, by hand or by using a spreading or packing tool. The paste is similar in its extrudability to the gelatin based hemostatic products such as commercially available SURGIFLO® Hemostatic Matrix.

[0111] A reference is made to the U.S. Pat. No. 7,109,163 Hemostatic compositions and devices, Pendharkar, et al., which is incorporated by reference herein in its entirety for all purposes. Pendharkar, et al. is describing hemostatic compositions with a peak expression force of no greater than 22.4 lbs. As used therein, “Peak Expression Force” is the peak force value required to extrude compositions from a pre-filled 10 cc Becton Dickinson (BD) luer syringe fitted with a 14 gauge angiocatheter tip, as described in the examples of the specification in the cited patent. Conversion of the force of the above reference into Newtons yields a force of 99.6 N.

[0112] According to the article “The Biomechanics and Optimization of the Needle-Syringe System for Injecting Triamcinolone Acetonide into Keloids”, by Anthony Vo, et al., Journal of Medical Engineering, 2016, Volume 2016, Article ID 5162394, the pressure that can be generated for any syringe at a predetermined speed depends on the force exerted by the physician. An injection is conventionally performed with the thumb pushing on the plunger while the ipsilateral index and middle fingers are used to stabilize the syringe flanks. In this position, the average maximum force that can be generated is 79.8 N (males: 95.4 N, females: 64.1N). (citing Astin A. D. “Finger Force Capability: Measurement and Prediction Using Anthropometric and Myoelectric Measures”, Blacksburg, Va., USA: Faculty of the Virginia Polytechnic Institute and State University; Master of Science Thesis; 1999).

[0113] Maximum isometric injection forces for two types of syringes were reported in the article “The effect of a new syringe design on the ability of rheumatoid arthritis patients to inject a biological medication”, by Ali Sheikhzadeh et al., Applied ergonomics, 43 (2012) 368-375. The maximum isometric force on syringe plunger with the plunger depressed halfway was 51.99 and 77.11 N from different syringes; while with the plunger fully depressed, forces of 45.30 N and 66.51 N were observed.

[0114] However, higher expression forces can be utilized in the expression of the flowable paste of the present disclosure wherein practitioner utilizes both hands by grasping the body of the device (such as dual barrel syringe) with one hand and using another hand to depress plungers to express the semi-solid paste, or by using both thumbs pushing on the plunger. At least a double of the force can be thus developed and the present semi-solid paste should be expressible at forces at least double of the above referenced force of 79.8 N i.e. at forces up to about 159.6 N or about 160 N. Further, with power amplified or powered expression systems, such as gear-assisted, spring assisted, or motorized systems, even higher expression forces can be developed. However, the preferred way to express the paste is manual, by hand-operating an expression plunger.

[0115] While the invention has been described above with reference to specific embodiments thereof, it is apparent that many changes, modifications, and variations can be made without departing from the inventive concept disclosed herein. Accordingly, it is intended to embrace all such changes, modifications, and variations that fall within the spirit and broad scope of the appended claims.